CELLUMED (049180) | AccidentalOrder

KOSDAQ · 1,009 KRW · As of Aug 26, 2026 close

1Y Close · As of Aug 26, 2026

Mkt Cap

84.0B

Rev (2025)

140.2B

Op Inc (2025)

-5.1B

Net Inc (2025)

-2.2B

PBR

10.01

52W

0K~2K

CELLUMED operates in the Pharmaceuticals sector.

Legal name: CELLUMED CO., LTD.

In fiscal year 2025, CELLUMED (049180) reported revenue of 140.2 billion KRW, up 8.6% from 129.1 billion KRW a year earlier.

Operating profit was -5.1 billion KRW and net income was -2.2 billion KRW in the same year.

As of the Aug 26, 2026 close, the market capitalization was 84.0 billion KRW, with a P/B of 10.01.

These figures can be verified in the DART filing (receipt no. 20260710000233).

Year	Rev	Op Inc	Net Inc
2025	140.2B	-5.1B	-2.2B
2024	129.1B	-6.8B	-31.8B
2023	95.6B	-10.5B	-37.9B

5 applicable out of 8 items

Semi-Annual Review Adverse Opinion (Capital Erosion 50%+ or Equity Below 1B)

Semi-Annual Report (2026.06)

Checks

5 of 8 checked items currently applicable.

Market Cap & Price: Market cap is above the delisting threshold.

Administrative Designation: 3 administrative designation criteria met. [source]

Audit Opinion: Audit opinion: Disclaimer of opinion. [source]

Convertible Bonds: Convertible bonds outstanding with 0.01% potential dilution.

Capital Increase: No capital-increase filings in the last 180 days.

Treasury Stock: No treasury stock filings.

Embezzlement & Litigation: 4 embezzlement/litigation filing(s) in the last 180 days. [source]

Major Shareholder Change: No major shareholder changes in the last 180 days.

Market Action: 8 market action(s) (trading halt, delisting, etc.) recorded. [source]

These checks are mechanical tests of disclosed figures and do not constitute investment advice or recommendations.

Date	Filing
2026-08-14	Semi-Annual Review Adverse Opinion (Capital Erosion 50%+ or Equity Below 1B)
2026-08-14	Semi-Annual Report (2026.06)